Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Pituitary Neoplasms 3Acromegaly 2Prostatic Neoplasms 1Prolactinoma 1Prolactin Deficiency, Isolated 1Pituitary ACTH Hypersecretion 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hyperprolactinemia 1Dumping Syndrome 1Brain Neoplasms 1

Interventions

Octreotide 4lanreotide 3Everolimus 3Carboplatin 2surufatinib 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Cisplatin 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neuroendocrine Tumors × Cabergoline × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡